Abstract
This review considers the hypolipidaemic drugs that act on the gastrointestinal (GI) tract. We searched PubMed up to April 2008 and included randomized controlled trials, original papers, review articles and case reports. Bile acid sequestrants (BAS) have a well-established low density lipoprotein cholesterol (LDL-C) lowering effect, but may increase triglyceride (TG) levels. BAS have no systematic adverse effects, but are associated with increased GI adverse effects and interactions with the absorption of other drugs. Ezetimibe improves LDL-C, high density lipoprotein cholesterol and TG levels, as monotherapy or especially when given with a statin. Ezetimibe has not been associated with serious adverse effects. Ezetimibe has not been evaluated in large clinical trials with cardiovascular disease (CVD) endpoints. Phytosterols are not licensed drugs; they have a well-established LDL-C lowering effect, but there are no large long-term randomized clinical trials investigating their effects on CVD events. Orlistat is an antiobesity drug with a small additional LDL-C lowering effect independent of weight loss. Orlistat-assisted weight loss improves the overall lipid profile, carbohydrate metabolism and transaminase activities. However, its use should be limited to weight reduction. This drug is associated with increased GI adverse effects.
Keywords: Colestyramine, colestipol, colesevelam, colestimide, ezetimibe, phytosterols, orlistat, low density lipoprotein cholesterol
Current Pharmaceutical Design
Title: Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Volume: 15 Issue: 5
Author(s): T. D. Filippatos and D. P. Mikhailidis
Affiliation:
Keywords: Colestyramine, colestipol, colesevelam, colestimide, ezetimibe, phytosterols, orlistat, low density lipoprotein cholesterol
Abstract: This review considers the hypolipidaemic drugs that act on the gastrointestinal (GI) tract. We searched PubMed up to April 2008 and included randomized controlled trials, original papers, review articles and case reports. Bile acid sequestrants (BAS) have a well-established low density lipoprotein cholesterol (LDL-C) lowering effect, but may increase triglyceride (TG) levels. BAS have no systematic adverse effects, but are associated with increased GI adverse effects and interactions with the absorption of other drugs. Ezetimibe improves LDL-C, high density lipoprotein cholesterol and TG levels, as monotherapy or especially when given with a statin. Ezetimibe has not been associated with serious adverse effects. Ezetimibe has not been evaluated in large clinical trials with cardiovascular disease (CVD) endpoints. Phytosterols are not licensed drugs; they have a well-established LDL-C lowering effect, but there are no large long-term randomized clinical trials investigating their effects on CVD events. Orlistat is an antiobesity drug with a small additional LDL-C lowering effect independent of weight loss. Orlistat-assisted weight loss improves the overall lipid profile, carbohydrate metabolism and transaminase activities. However, its use should be limited to weight reduction. This drug is associated with increased GI adverse effects.
Export Options
About this article
Cite this article as:
Filippatos D. T. and Mikhailidis P. D., Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract, Current Pharmaceutical Design 2009; 15 (5) . https://dx.doi.org/10.2174/138161209787315738
DOI https://dx.doi.org/10.2174/138161209787315738 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Applications of Doebner, Doebner-von Miller and Knoevenagel-Doebner Reactions in Organic Syntheses
Current Organic Synthesis Big Pharma's Recent Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs Systemic Application of Anti-inflammatory Agents in Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Screening and Analysis of Hypolipidemic Components from Shuangdan Capsule Based on Pancreatic Lipase
Current Bioinformatics HPLC as a Tool in Medicinal Chemistry for the Monitoring of Tricyclic Antidepressants in Biofluids
Mini-Reviews in Medicinal Chemistry Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Bioactives in Disease Prevention and Health Promotion: Exploiting Combinatorial Effects
Current Bioactive Compounds C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways
Current Signal Transduction Therapy Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology Synergistic Antitumor Effect of 5-Fluorouracil Combined with Constituents from <i>Pleurospermum lindleyanum</i> in Hepatocellular Carcinoma SMMC-7721 Cells
Anti-Cancer Agents in Medicinal Chemistry Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges
Current Pharmaceutical Design Magnetic Resonance Perfusion Imaging Provides a Significant Tool for the Identification of Cardioembolic Stroke
Current Neurovascular Research Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Quantitative Coronary Angiography: Back to the Past
Recent Patents on Medical Imaging